Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Roy Vant Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead. Good morning, and thanks for joining today's call to review positive phase two results for brevacitinib and cutaneous sarcoidosis, and Reuven's financial results for the third quarter ended December 31, 2025. I'm Stephanie Lee with Reuven. Presenting today, we have Matt Klein, CEO of Reuven, and Ben Zimmer, CEO of Reuven. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.royvand.com. We'll also be providing the current slide numbers as we present to help you follow along. I would like to remind you that we will be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. So with that, I'll turn it over to Matt. Thanks, Steph, and thanks, everyone, for dialing in and listening this morning. I'm going to start our presentation on slide five. You know, I was sitting, talking to the team, it was about a week ago today, looking at a draft of this mor...